Barry Rockx, Ph.D.

Barry Rockx, Ph.D.

Assistant Professor, Department of Pathology

University of Texas Medical Branch
301 University Blvd,
Galveston, TX 77555-0610

Office: (409) 266-6904
Fax: (409) 266-6810
barockx@utmb.edu

« Back

Barry Rockx, Ph.D.

Professional Education

Degree Institution Field of Study Graduation Year
B.S.

Hogeschool West-Brabant, Etten-Leur, The Netherlands

Histology 1997
M.Sc. Vrije Universiteit, Amsterdam, The Netherlands Virology 1998
Ph.D.

Graduate School of Animal Health, Utrecht, The Netherlands

Virology 2004
Postdoctoral University of North Carolina, Chapel Hill, NC Virology 2004-2008

Honors

1999-2004 Ph.D. student, Diagnostic Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
2004 Emanuel Wolinsky Award for best article published in Clinical Infectious Diseases in 2002.
2004 Post-doctoral Research associate, Diagnostic Laboratory for Infectious Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
2004-2008 Post-Doctoral Research Associate, Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC
2008-2010 Research Fellow, Laboratory of Virology, Rocky Mountain Laboratories, DIR, NIAID, NIH
2010 Rising STAR award
2010-present Assistant Professor, Departments of Pathology and Microbiolgy & Immunology, University of Texas Medical Branch, Galveston, TX

Research Interests

Dr. Rockx’s research interests are focused on virus-host interactions, molecular pathogenic mechanisms, and the host responses following emerging high containment virus infection. His research will focus on the development and characterization of in vivo and in vitro models of Hendra (HeV) and Nipah virus (NiV) infection. HeV and NiV are two members of the genus Henipavirus (family Paramyxoviridea) that cause respiratory illness and encephalitis in humans and a variety of other mammals. The goal of these projects is to understand how these viruses infect the respiratory tract and spread to the central nervous system and to identify differences in routes of transmission and pathogenesis between different HeV and NiV strains.

A second area of interest is the development and testing of broadly protective therapeutics. The high mutation rate and heterogeneity of emerging zoonotic viruses is a major problem in developing therapeutics and therefore a key objective is the development of broadly cross-reactive reagents that will maximize the likelihood of protection against unknown future strain variants.

Selected Publications

Articles in Peer-Reviewed Journals:

    1. Rockx, B., de Wit, M., Vennema, H., Vinjé, J., de Bruin, E., van Duynhoven, Y., and Koopmans, M. Natural History of Human Calicivirus Infection: A Prospective Cohort Study. Clin Infect Dis 35, 246-53 (2002).
    2. Duizer, E., Bijkerk, P., Rockx, B., de Groot, A., Twisk, F., and Koopmans, M. Inactivation of Caliciviruses. Appl Environ Microbiol 70, 4538-43 (2004).
    3. Rockx, B., Bogers, W., Heeney, J., van Amerongen, G., and Koopmans, M. Experimental Norovirus Infections in Non-human Primates. J Med Vir 2005 Feb;75(2):313-20.
    4. Rockx, B., Vennema, H., Hoebe, C., Duizer, E., and Koopmans, M. Association of Histo-Blood Group Antigens and Susceptibility to Norovirus Infections. J Infect Dis. 2005 Mar 1;191(5):749-54
    5. Widdowson, M.A., Rockx, B., Schepp, R., Vinjé, J., van Duynhoven, Y., and Koopmans, M. Detection of Serum Antibodies to Bovine Norovirus in Veterinarians and the General Population in The Netherlands. J Med Virol. 2005 May;76(1):119-28
    6. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP. Characterization of the Homo- and Heterotypic Immune Responses after Natural Norovirus Infection. J Med Virol. 2005 Sep 19;77(3):439-446
    7. Rockx, B., van Asten, L., van den Wijngaard, C., Godeke, GJ., Goehring, L., Vennema, H., van der Avoort, H., van Pelt, W. and Koopmans, MP. Syndromic Surveillance in The Netherlands for the Early Detection of West Nile Virus Epidemic. Vector Borne Zoonotic Dis. 2006 Summer;6(2):161-9.
    8. Rockx, B., Sheahan, T., Donaldson, E., Harkema, J., Sims, A., Heise, H., Pickles, R., Cameron, M., Kelvin, D. and Baric, R. Synthetic Reconstruction of Zoonotic and Early Human SARS-CoV Isolates that Produce Fatal Disease in Aged Mice. J Virol. 2007 Jul;81(14):7410-23..
    9. Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L., Prabakaran, P., Rockx, B., Sidorov, I., Corti, D., Vogel, L., Feng, Y., Kim, J., Wabg, L., Baric, R., Lanzavecchia, A., Curtis, K., Nabel, G., Subbarao, K., Jiang, S. And Dimitrov, D. Potent Cross-Reactive Neutralization of SARS Coronavirus Isolates by Human Monoclonal Antibodies. Proc Natl Acad Sci USA. 2007 Jul 17;104(29):12123-8.
    10. Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R. Mechanisms of Zoonotic SARS-CoV Host Range Expansion in Human Airway Epithelium. J Virol. 2008 Mar;82(5):2274-85
    11. Rockx, B., Corti, D., Sheahan, T., Donaldson, E., Stadler, K, Lanzavecchia, A. and Baric, R. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection Against Lethal Human and Zoonotic SARS-CoV Challenge. J Virol. 2008 Apr;82(7):3220-35.
    12. Sheahan T, Rockx B, Donaldson E, Corti D, Baric R. Pathways of Cross Species Transmission of Synthetically Reconstructed Zoonotic SARS-CoV. J Virol. 2008. Sep;82(17):8721-32
    13. Becker, M., Graham, R., Donaldson, E., Rockx, B., Sims, A., Sheahan, T., Corti, D., Jonhston, R., Baric, R. and Denison, M. Synthetic Reconstruction of an Infectious Bat SARS-like Coronavirus. PNAS. Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19944-9.
    14. Rockx, B., Baas, T., Zornetzer, G., Haagmans, B., Sheahan, T., Teal., T, van den Brand, J., Katze, M. and Baric, R. Early Upregulation of ARDS-Related Genes Promotes Lethal Disease in a Mouse Model of SARS-CoV Infection. J Virol. 2009 Jul;83(14):7062-74. Epub 2009 May 6.
    15. Rockx, B., Donaldson, E., Corti, D., Sheahan, T., Lanzavecchia, A. and Baric, R. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis. 2010 Mar 15;201(6):946-55.
    16. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, Liu W, Ashour J, Shupert WL, Holbrook MR, Barrett AD, Mason PW, Bloom ME, Garcia-Sastre A, Khromykh AA, Best SM. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol. 2010 Jan 27.
    17. Rockx, B., Bossart, KN., Feldmann, F., Geisbert, JB., Hickey, AC., Brining, D., Callison, J., Safronetz, D., Marzi, A., Kercher, L., Long, D., Broder, CC., Feldmann, H., Geisbert, TW. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol. 2010 Jul 21.
    18. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W, Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric RS. Successful Vaccination Strategies that Protect Aged Mice from Lethal Influenza and Lethal Heterologous SARS-CoV Challenge.J Virol. 2010 Oct 27. [Epub ahead of print]
    19. Porotto M, Rockx B, Yokoyama CC, Talekar A, Devito I, Palermo LM, Liu J, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A. Inhibition of Nipah Virus Infection In Vivo: Targeting an Early Stage of Paramyxovirus Fusion Activation during Viral Entry. PLoS Pathog. 2010 Oct 28;6(10):e1001168.

NIH Biosketch